

Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: A Growing Epidemic and Its Cardiometabolic Implications

Dr. Ankatagari Dinesh¹, Dr. V. Padma², Dr. Vinatha Mc³, Dr. S V Sathyapriya⁴, Dr. Jayakaran V⁵

¹ Post Graduate, General Medicine, Sree Balaji Medical College and Hospital, Chromepet, Chennai.

Email: naidu.dinesh.dn@gmail.com

² Dr. V. Padma (HD0004). Email: padmaramesh86@Yahoo.com, Contact: 98401 66947, TNMC No: 57218

³ Dr. Vinatha MC. Email: Vinathamadhurkar@gmail.com, ORCID: 0000-0003-4317-6842

⁴ Dr. S V Sathyapriya (HD1035). Email: svsatz1994@gmail.com, Contact: 90037 91637, TNMC No: 123933

⁵ Dr. Jayakaran V, Assistant Professor.

Received: 20th Feb, 2026 | Revised: 4th Mar, 2026 | Accepted: 25th Mar, 2026 | Available Online: 10th Apr, 2026

ABSTRACT

Non-alcoholic fatty liver disease (NAFLD) has emerged as the most common chronic liver disease worldwide and is strongly associated with type 2 diabetes mellitus (T2DM). The coexistence of NAFLD and T2DM significantly increases the risk of liver fibrosis, cirrhosis, and cardiovascular disease. This review highlights the pathophysiological links, clinical implications, diagnostic strategies, and therapeutic approaches for NAFLD in patients with T2DM. Early recognition and targeted management are essential to reduce both hepatic and cardiovascular complications.

Keywords: NAFLD, Type 2 Diabetes Mellitus, Insulin resistance, Liver fibrosis, Cardiovascular risk.

How to cite this article: Ankatagari Dinesh, Padma V, Vinatha MC, Sathyapriya SV, Jayakaran V. Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: A Growing Epidemic and Its Cardiometabolic Implications. *Int J Drug Deliv Technol.* 2026;16(29s):422-423. DOI: 10.25258/ijddt.16.29s.52

Source of support: Nil.

Conflict of interest: The authors declare no conflict of interest.

1. Introduction

The global burden of NAFLD is rapidly increasing, paralleling the rise in obesity and T2DM. NAFLD is now recognized not only as a liver disease but also as a systemic metabolic disorder. Patients with T2DM are at particularly high risk of developing progressive liver disease and cardiovascular complications.

2. Pathophysiological Link Between NAFLD and T2DM

The relationship between NAFLD and T2DM is bidirectional.

Key mechanisms:

- **Insulin resistance** → Increased lipolysis → Free fatty acid influx to liver
 - **Hepatic steatosis** → Impaired insulin signaling
 - **Inflammation and oxidative stress**
 - **Gut microbiota alterations**
- This vicious cycle accelerates disease progression.

3. Spectrum of NAFLD

- Simple steatosis (NAFL)

- Non-alcoholic steatohepatitis (NASH)
- Fibrosis → Cirrhosis
- Hepatocellular carcinoma (HCC)
- Patients with T2DM are more likely to progress to advanced stages.

4. Clinical Significance in T2DM

- Increased risk of liver-related morbidity
- Strong association with **atherosclerotic cardiovascular disease (ASCVD)**
- Increased overall mortality
- Cardiovascular disease remains the leading cause of death in NAFLD patients.

5. Diagnosis

5.1 Laboratory Findings

- Mild elevation of ALT/AST
- Elevated triglycerides

5.2 Imaging

- Ultrasound (screening tool)
- FibroScan (liver stiffness measurement)
- MRI (gold standard for fat quantification)

Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: A Growing Epidemic and Its Cardiometabolic Implications

5.3 Non-Invasive Scores

- FIB-4 score
- NAFLD fibrosis score

6. Screening Recommendations

- All patients with T2DM should be evaluated for NAFLD
- High-risk patients should undergo fibrosis assessment

7. Management Strategies

7.1 Lifestyle Modification

- Weight loss (7–10%) improves steatosis and fibrosis
- Diet: Low carbohydrate, Mediterranean diet
- Exercise improves insulin sensitivity

7.2 Pharmacotherapy

Antidiabetic Drugs with Benefit

- **Pioglitazone** → Improves NASH
- **GLP-1 receptor agonists** → Weight loss + liver fat reduction
- **SGLT2 inhibitors** → Reduce hepatic fat

Other Therapies

- Vitamin E (selected patients)
- Statins (safe and beneficial for CV risk)

8. Cardiovascular Implications

NAFLD is an independent risk factor for:

- Coronary artery disease
- Stroke
- Heart failure

Mechanisms:

- Endothelial dysfunction
- Pro-inflammatory state
- Dyslipidemia

9. Emerging Therapies

- FXR agonists (obeticholic acid)
- PPAR agonists
- Anti-fibrotic agents

10. Future Directions

- Routine screening in diabetes clinics
- Integration into cardiometabolic care
- Development of targeted therapies

11. Clinical Implications

- NAFLD should be considered a **cardiometabolic disease**
- Multidisciplinary approach required
- Early intervention can prevent complications

12. Conclusion

NAFLD in T2DM represents a major and growing health challenge. Its strong association with cardiovascular disease and progressive liver damage necessitates early diagnosis and comprehensive management. Addressing NAFLD is essential for improving long-term outcomes in diabetic patients.

References (Vancouver Style – Sample)

1. Younossi ZM, et al. Global epidemiology of NAFLD. *Hepatology*. 2016.
2. Chalasani N, et al. AASLD guidelines for NAFLD. *Hepatology*. 2018.
3. Mantovani A, et al. NAFLD and cardiovascular disease. *Diabetes Care*. 2020.
4. Cusi K. Role of insulin resistance in NAFLD. *Gastroenterology*. 2012.
5. Armstrong MJ, et al. GLP-1 therapy in NASH. *Lancet*. 2016.